Digestive Malignancy without CC/MCC DRG Reimbursement Guide

DRG 376 addresses inpatient admissions for digestive malignancy cases without Complication or Comorbidity or Major Complication or Comorbidity, encompassing lower-severity cancer-related surgical and non-surgical care. It matters for inpatient reimbursement because grouping by complication status determines relative Medicare Severity Diagnosis-Related Group payment levels and hospital resource allocation.

DRG 376 Overview

DRG 376 covers inpatient hospital admissions for digestive system malignancies without qualifying Complication or Comorbidity or Major Complication or Comorbidity. It typically includes patients undergoing definitive surgical procedures or diagnostic and palliative treatments when no CC or MCC is coded. This Diagnosis-Related Group matters for Medicare payment because it groups relatively lower-severity cancer admissions into a distinct payment category, affecting average reimbursement and resource expectations. Accurate coding of comorbid conditions and procedures determines whether an admission stays in this group or shifts to a higher-paying group.

Perioperative multimodal therapy trials examining the sequencing and combination of surgery with neoadjuvant or adjuvant systemic therapy and/or radiation in resectable digestive tract cancers. These studies enroll patients admitted for definitive surgical resection of localized gastrointestinal malignancies (esophagus, stomach, small bowel, colon, rectum) without major comorbid complications, and compare different timing strategies (preoperative chemotherapy ± radiation versus postoperative therapy), regimens, or durations to optimize pathologic response and margin-negative resection rates. Results matter to providers and payers because improved perioperative protocols can reduce length of stay, readmission, recurrence risk, and downstream costs associated with additional therapies or complications.
Comparative effectiveness trials of minimally invasive versus open surgical approaches and enhanced recovery protocols for patients undergoing index hospitalization for digestive malignancy resection. These pragmatic studies enroll typical inpatient surgical candidates and evaluate outcomes such as intraoperative complications, postoperative morbidity, time to return of bowel function, hospital resource utilization, and short-term mortality between laparoscopy/robotic techniques and traditional open surgery, often incorporating standardized ERAS pathways. Evidence from these trials informs surgical decision-making, coding and reimbursement considerations, and payer assessments of cost-effectiveness tied to shorter LOS and reduced complication-related expenditures for this DRG cohort.
Post-discharge and survivorship outcomes research focusing on functional recovery, surveillance strategies, and health-related quality of life after hospitalization for digestive malignancy without major complications. Cohorts include patients discharged following uncomplicated resections or nonoperative inpatient management, tracking readmissions, need for adjuvant therapy, nutritional status, and symptom burden over months to years to identify predictors of utilization and gaps in transitional care. This research is relevant to providers and payers because it identifies opportunities to reduce preventable readmissions, tailor follow-up services, and allocate resources for outpatient supportive care that can lower overall costs while maintaining oncologic outcomes.

Perioperative multimodal therapy trials examining the sequencing and combination of surgery with neoadjuvant or adjuvant systemic therapy and/or radiation in resectable digestive tract cancers. These studies enroll patients admitted for definitive surgical resection of localized gastrointestinal malignancies (esophagus, stomach, small bowel, colon, rectum) without major comorbid complications, and compare different timing strategies (preoperative chemotherapy ± radiation versus postoperative therapy), regimens, or durations to optimize pathologic response and margin-negative resection rates. Results matter to providers and payers because improved perioperative protocols can reduce length of stay, readmission, recurrence risk, and downstream costs associated with additional therapies or complications.
Comparative effectiveness trials of minimally invasive versus open surgical approaches and enhanced recovery protocols for patients undergoing index hospitalization for digestive malignancy resection. These pragmatic studies enroll typical inpatient surgical candidates and evaluate outcomes such as intraoperative complications, postoperative morbidity, time to return of bowel function, hospital resource utilization, and short-term mortality between laparoscopy/robotic techniques and traditional open surgery, often incorporating standardized ERAS pathways. Evidence from these trials informs surgical decision-making, coding and reimbursement considerations, and payer assessments of cost-effectiveness tied to shorter LOS and reduced complication-related expenditures for this DRG cohort.
Post-discharge and survivorship outcomes research focusing on functional recovery, surveillance strategies, and health-related quality of life after hospitalization for digestive malignancy without major complications. Cohorts include patients discharged following uncomplicated resections or nonoperative inpatient management, tracking readmissions, need for adjuvant therapy, nutritional status, and symptom burden over months to years to identify predictors of utilization and gaps in transitional care. This research is relevant to providers and payers because it identifies opportunities to reduce preventable readmissions, tailor follow-up services, and allocate resources for outpatient supportive care that can lower overall costs while maintaining oncologic outcomes.

OpenPayer

Summary & Overview

Digestive Malignancy without CC/MCC: Inpatient Reimbursement Overview

DRG 376 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes